PUTTINI, MIRIAM
PUTTINI, MIRIAM
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years
2011 GAMBACORTI PASSERINI, C; Antolini, L; Piazza, R; Guilhot, F; Deininger, M; Fava, C; Nagler, A; Morra, E; Abruzzese, E; D'Emilio, A; Stagno, F; le Coutre, P; Monroy, R; Santini, V; Pane, F; Giraldo, P; Assouline, S; Durosinmi, M; Leeksma, O; Pogliani, E; Pavesi, F; Puttini, M; Rizzo, C; Dilda, I; Mori, S; Kim, D; Valsecchi, M
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
2011 GAMBACORTI PASSERINI, C; Antolini, L; Mahon, F; Guilhot, F; Deininger, M; Fava, C; Nagler, A; Della Casa, C; Morra, E; Abruzzese, E; D'Emilio, A; Stagno, F; le Coutre, P; Monroy, R; Santini, V; Martino, B; Pane, F; Piccin, A; Giraldo, P; Assouline, S; Durosinmi, M; Leeksma, O; Pogliani, E; Puttini, M; Jang, E; Reiffers, J; Valsecchi, M; Kim, D
Imatinib long term effects study: three years of follow-up and assessment
2009 Tornaghi, L; Meneghetti, I; Dilda, I; Puttini, M; Piazza, R; Antolini, L; Kim, D; Nagler, A; Durosinmi, M; Morra, E; Rambaldi, A; Abruzzese, E; Stagno, F; Saglio, G; Pane, F; Guilhot, F; Le Coutre, P; Giraldo, P; Pogliani, E; Valsecchi, M; GAMBACORTI PASSERINI, C
Characterization of compound 584, an Abl kinase inhibitor with lasting effects
2008 Puttini, M; Redaelli, S; Moretti, L; Brussolo, S; Gunby, R; Mologni, L; Marchesi, E; Cleris, L; Donella deana, A; Drueckes, P; Sala, E; Lucchini, V; Kubbutat, M; Formelli, F; Zambon, A; Scapozza, L; GAMBACORTI PASSERINI, C
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
2007 Galietta, A; Gunby, R; Redaelli, S; Stano, P; Carniti, C; Bachi, A; Tucker, P; Tartari, C; Huang, C; Colombo, E; Pulford, K; Puttini, M; Piazza, R; Ruchatz, H; Villa, A; Donella deana, A; Marin, O; Perrotti, D; GAMBACORTI PASSERINI, C
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy
2007 Gunby, R; Sala, E; Tartari, C; Puttini, M; GAMBACORTI PASSERINI, C; Mologni, L
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic
2006 Puttini, M; Coluccia, A; Boschelli, F; Franceschino, A; Tomaghi, L; Ahmed, S; Redaelli, S; Piazza, R; Magistroni, V; Andreoni, F; Scapozza, L; Formelli, F; GAMBACORTI PASSERINI, C
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
2006 Puttini, M; Coluccia, A; Boschelli, F; Cleris, L; Marchesi, E; Donella Deana, A; Ahamed, S; Redaelli, S; Piazza, R; Magistroni, V; Andreoni, F; Scapozza, L; Formelli, F; GAMBACORTI PASSERINI, C
Inhibition of RET tyrosine kinase by SU5416
2006 Mologni, L; Sala, E; Cazzaniga, S; Rostagno, R; Kuoni, T; Puttini, M; Bain, J; Cleris, L; Redaelli, S; Riva, B; Formelli, F; Scapozza, L; GAMBACORTI PASSERINI, C
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins
2005 Galietta, A; Gunby, R; Stano, P; Tucker, P; Carniti, C; Ruchatz, H; Piazza, R; Huang, C; Tartari, C; Puttini, M; Pulford, K; Colombo, E; Bachi, A; GAMBACORTI PASSERINI, C